Living with chronic pain?
It’s time to explore
a new option

See if the FAST Study is right for you.

Chronic pain affects 1 in 5 adults, and can impact nearly every aspect of daily life - from work performance, to family life, to social interactions.1 For many people, this pain affects the lower back and/or legs, and can be caused by a variety of underlying conditions.

If you’ve struggled with chronic low back and/or leg pain for at least 6 months that has not responded to other treatments, you may be a candidate for the FAST Study. The study uses the WaveWriter™ Spinal Cord Stimulator System - an FDA-approved, drug-free therapy shown to effectively relieve pain and improve quality of life.2,3

What is WaveWriter™ SCS?

The WaveWriter Spinal Cord Stimulator (SCS) System is an FDA-approved therapy for people with chronic pain. Spinal cord stimulation is a safe, drug-free solution for treating chronic pain that uses a small implanted device called a neurostimulator. The neurostimulator sends mild pulses of energy to the spinal cord to mask or modify pain signals before you feel them. SCS systems also come with a mobile, handheld remote control that lets you adjust the stimulation to your needs.

A key benefit of SCS is that you can try it for a period of time (usually 3 - 7 days) to decide whether it’s right for you. To try out SCS, you’ll simply be fitted with a temporary device that works like an implanted system, but you will use a small external generator (that can easily hide under your clothing). If after the trial period you are satisfied with your pain relief, you can choose to have the system implanted. This is done through a short, reversible surgical procedure to place the neurostimulator beneath the skin.

The WaveWriter SCS System provides you the right therapy, right where you need it. Some therapies replace your pain with a tingling sensation. Others use a type of stimulation you don’t feel at all. With WaveWriter you can choose the therapy that works best for you - or use both at the same time. This ability to deliver multiple therapies simultaneously has been clinically providen to provide greater pain relief.4

 

The FAST Study

Doctors at select US centers are conducting the FAST Study to gather additional information about WaveWriter SCS therapy for treating chronic low back and/or leg pain. If you qualify and choose to join the FAST Study, you will be treated by a local physician specialist and will be compensated for your time and travel to attend regular follow-up visits to evaluate your progress.

Why Participate?

If you’ve struggled with chronic low back and/or leg pain for at least 6 months that has not responded to other treatments, you may be a candidate for the FAST Study. The study uses the WaveWriter Spinal Cord Stimulator System - an FDA-approved drug-free therapy shown to effectively relieve pain and improve quality of life. If you qualify and choose to join the FAST study you will receive:

  • Evaluations of your pain by a local physician specialist
  • Treatment with the WaveWriter SCS System
  • Compensation for your time and effort to attend routine follow-up visits over a 2-year period
  • A smartwatch for use during the study, which can be kept for personal use after your study participation is complete

See If You Qualify

To see if you might qualify for the FAST Study, and to get connected with your local study center to learn more, please take the questionnaire below:

 

References:

  1. Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:1001–1006.
  2. Veizi E, Hayek SM, North J, et al. Spinal cord stimulation (SCS) with anatomically guided (3D) neural targeting shows superior chronic axial low back pain relief compared to traditional SCS—LUMINA Study. Pain Med. 2017;18(8):1534-1548.
  3. Thomson SJ, Kruglov D, Duarte RV. A spinal cord stimulation service review from a single centre using a single manufacturer over a 7.5 year follow-up period. Neuromodulation. 2017;20(6):589-599. N=321
  4. 4. North, James, MD. WHISPER: A Multicenter, Prospective Randomized Controlled Trial Evaluating Subperception SCS at ≤ 1.2 kHz. Presentation at North American Neuromodulation Society (NANS), Las Vegas, NV, January 11-14, 2018. (N=70)